Agios Pharmaceuticals, Inc. AGIO R2KR3KPHARMA
Company Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $54.03M (+48.0% YoY); net profit $-412.78M.
- Trailing 12 Months Year-on-year growth — revenue +259.3%, earnings -161.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.22% |
| 1 Year: | 259.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -161.27% |
Stock Price Performance
| 1 Year: | -9.59% |
| 6 Months: | +20.50% |
| 3 Months: | +17.00% |
| 1 Month: | +3.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)45.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 27.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGIO Agios Pharmaceuticals, Inc. R2KR3KPHARMA | 33.10 | -4.72 | $1.98B | 0.00% | -38.86% | -34.34% | 7.22% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 11.36M | - | 8.76M | 40.41M | 15.20M | 30.01M | 30.23M | 26.22M | 26.02M | 35.44M | 87.10M | 37.35M | 34.71M | 44.05M | 0 | 0 | 0 | - | 832.00K | 5.58M | 3.52M | 5.61M | 6.71M | 7.40M | 8.19M | 8.62M | - | - | - | 12.46M | 12.88M | 19.97M | 20.75M | 44.74M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 1.68M | 1.88M | 1.32M | 3.00M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.75M | 11.20M | 18.09M | 19.43M | 41.75M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.81M | 128.07M | 139.67M | 129.45M | 152.30M |
| Operating Income | -23.59M | -56.47M | -63.51M | -57.41M | -67.05M | -84.60M | -79.02M | -90.13M | -94.01M | -72.95M | -99.16M | -96.36M | -97.48M | -113.86M | -109.06M | -105.93M | -87.03M | -83.26M | -80.29M | -92.43M | -91.22M | -91.22M | -91.15M | - | -101.14M | -97.64M | -91.09M | -90.61M | -93.70M | -100.90M | -92.07M | -105.82M | - | - | - | -127.06M | -116.87M | -121.58M | -110.03M | -110.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -125.80M | -115.50M | -120.31M | -108.66M | -109.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -112.02M | -103.43M | -109.06M | -99.11M | -100.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.12M | -8.88M | - | - | 0 | -1.02M | - | - |
| Net Income | -23.20M | -55.95M | -62.83M | -23.20M | -66.17M | -83.08M | -77.14M | - | -90.83M | -68.75M | -94.66M | - | -93.08M | -109.87M | -106.17M | - | -40.26M | -90.48M | -98.98M | - | 1.87B | -86.22M | -88.77M | - | -94.77M | -91.81M | -81.75M | -81.02M | -83.81M | -91.32M | -81.55M | -96.12M | - | - | - | -112.02M | -103.43M | -108.04M | -99.11M | -100.70M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.59 | -1.31 | -1.43 | -1.41 | 26.95 | -1.41 | -1.56 | -1.74 | -1.74 | -1.68 | -1.49 | -1.47 | -1.51 | -1.64 | -1.45 | -1.69 | 16.22 | - | -1.55 | -1.93 | -1.78 | - | -1.69 | -1.69 |
| R&D Expense | 44.04M | 50.80M | 60.64M | - | 62.73M | 79.82M | 72.92M | - | 78.22M | 86.73M | 82.56M | - | 95.58M | 107.39M | 101.67M | - | 55.36M | 54.09M | 51.94M | - | 57.67M | 62.01M | 64.00M | - | 70.12M | 74.52M | 64.97M | 67.30M | 68.89M | 81.84M | 68.62M | 77.40M | 72.45M | - | 72.74M | 91.94M | 86.80M | - | 81.15M | 100.75M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.84M | 25.11M | 25.55M | 65.36M | 59.12M | 69.89M | 43.01M | 94.39M | 117.91M | 0 | - | 14.24M | 26.82M | 36.50M | 54.03M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 2.88M | 4.17M | 6.34M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 12.54M | 23.94M | 32.33M | 47.68M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 401.58M | 415.43M | 458.07M | 519.82M |
| Operating Income | -16.63M | -23.00M | -38.88M | -54.13M | -118.70M | -200.99M | -320.79M | -362.48M | -316.27M | -335.92M | - | -389.05M | -391.49M | -425.74M | -472.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -380.48M | -384.86M | -420.08M | -466.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -231.80M | -352.09M | 717.97M | -413.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 44.24M | -1.02M |
| Net Income | -23.71M | -20.10M | -39.41M | -53.50M | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -327.37M | - | -231.80M | -352.09M | 673.73M | -412.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | -6.86 | -4.74 | - | -4.23 | -6.33 | 11.64 | -7.12 |
| R&D Expense | 31.25M | 41.04M | 54.50M | 100.37M | 141.83M | 220.16M | 292.68M | 341.32M | 214.26M | 220.81M | 256.97M | 279.91M | 295.53M | 301.29M | 339.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 137.01M | 201.21M | 491.90M | 420.06M | 619.09M | 614.40M | 858.46M | 890.74M | 852.95M | - | 1.24B | 937.12M | 1.66B | 1.30B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 832.77M | 833.84M | 965.60M | 942.05M |
| Cash & Equivalents | 77.88M | 117.66M | 91.30M | 71.56M | 14.03M | 71.76M | 160.75M | 102.72M | 70.50M | 80.93M | 127.44M | - | 139.26M | 88.20M | 76.25M | 89.13M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 8.49M | 19.08M | 27.62M | 32.92M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 2.21M | 2.81M | 4.11M | 10.58M |
| Total Liabilities | - | - | - | - | - | - | 260.50M | 238.89M | 170.92M | 250.21M | 453.45M | - | 137.90M | 126.10M | 122.24M | 104.11M |
| Current Liabilities | - | - | 35.11M | 36.93M | 61.09M | 52.89M | 88.43M | 94.94M | 93.50M | 92.89M | 94.39M | - | 62.63M | 67.95M | 81.16M | 82.21M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 85.66M | 72.00M | 56.99M | 40.21M |
| Total Equity | -29.59M | -52.78M | -72.02M | 131.48M | 424.37M | 345.12M | 358.59M | 375.50M | 687.54M | 640.53M | 399.50M | - | 1.10B | 811.02M | 1.54B | 1.19B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 71.26M | 72.16M | 73.37M | 74.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.22M | -49.55M | -56.40M | - | -76.95M | 38.56M | -285.23M | -304.42M | -370.62M | -290.76M | - | -309.48M | -296.06M | -389.84M | -372.98M |
| Investing Cash Flow | -22.36M | 23.04M | -87.22M | - | 128.31M | -119.35M | -57.91M | -273.82M | 91.44M | 75.75M | - | 243.26M | 239.57M | 363.44M | 377.18M |
| Financing Cash Flow | 77.36M | 142.00K | 123.88M | - | 6.37M | 169.78M | 285.11M | 546.02M | 289.61M | 261.52M | - | 2.35M | 5.43M | 14.44M | 8.68M |
| Capital Expenditure | -1.91M | -1.48M | -1.29M | -2.22M | -20.16M | -9.91M | -4.63M | -6.99M | -12.03M | -14.11M | - | -4.88M | -18.50M | -1.69M | -14.32M |
| Free Cash Flow | -17.12M | -51.02M | -57.69M | - | -97.11M | 28.65M | -289.86M | -311.41M | -382.65M | -304.87M | - | -314.36M | -314.56M | -391.53M | -387.29M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -63.87M | -51.05M | -11.96M | 12.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating Margin % | -76.2% | -91.6% | -152.2% | -82.8% | -200.8% | -287.6% | -745.8% | -384.0% | -268.2% | - | - | -2,732.1% | -1,459.5% | -1,166.5% | -873.9% |
| Net Margin % | -108.6% | -80.1% | -154.2% | -81.9% | -199.1% | -284.0% | -731.6% | -366.6% | -349.0% | - | - | -1,627.8% | -1,312.6% | 1,845.9% | -764.0% |
| ROE % | 44.9% | 27.9% | -30.0% | -12.6% | -34.1% | -55.3% | -83.8% | -50.3% | -64.2% | -81.9% | - | -21.1% | -43.4% | 43.7% | -34.6% |
| ROCE % | - | -22.6% | -23.7% | -12.6% | -32.3% | -37.9% | -61.8% | -47.4% | -39.6% | -44.3% | - | -33.1% | -45.0% | -26.9% | -38.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.81% | 6.46M | $215.11M |
| 2 | Farallon Capital Management LLC | 9.91% | 5.92M | $197.17M |
| 3 | State Street Corporation | 5.92% | 3.53M | $117.74M |
| 4 | Lynx1 Capital Management Lp | 5.71% | 3.41M | $113.59M |
| 5 | Shaw D.E. & Co., Inc. | 5.20% | 3.11M | $103.53M |
| 6 | Vanguard Portfolio Management LLC | 4.85% | 2.90M | $96.57M |
| 7 | Vanguard Capital Management LLC | 4.49% | 2.68M | $89.36M |
| 8 | Armistice Capital, LLC | 4.02% | 2.40M | $79.97M |
| 9 | Erste Asset Management GmbH | 3.61% | 2.15M | $71.80M |
| 10 | Nomura Asset Management International Inc | 3.54% | 2.11M | $70.33M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGIO
Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
Agios reports $44.7 million in Q2 mitapivat revenue and FDA priority review for sickle cell disease, while advancing pipeline diversification with cevidoplenib.
Agios Pharmaceuticals Q2 Earnings Call Highlights
Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company continued the U.S. thalassemia launch of…
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.
Agios scraps sickle cell drug programme on underwhelming Phase II data
This deals another blow to tebapivat’s development prospects following its May 2026 termination in MDS due to efficacy concerns.
AGIO — Frequently Asked Questions
What is the current share price of Agios Pharmaceuticals, Inc. (AGIO)?
As of 2026-09-07 16:24 PDT, Agios Pharmaceuticals, Inc. (AGIO) trades at $33.10 on NasdaqGS. Its 52-week range is $22.34 to $45.49.
What is the market capitalisation of AGIO?
Agios Pharmaceuticals, Inc. (AGIO) has a market capitalisation of $1.98B on NasdaqGS.
What is the P/E ratio of AGIO?
AGIO trades at a trailing price-to-earnings (P/E) ratio of -4.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.87.
What is the return on equity (ROE) of AGIO?
AGIO has a return on equity (ROE) of -34.34%. Its return on capital employed (ROCE) is -38.86%.
Is AGIO a good stock to buy?
This page provides a data-driven analysis of Agios Pharmaceuticals, Inc. (AGIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.